Regeneron Reports First Quarter 2021 Financial and Operating Results
News provided by
Share this article
TARRYTOWN, N.Y., May 6, 2021 /PRNewswire/
First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COV
TM(1)
First quarter 2021 Dupixent
First quarter 2021 GAAP diluted EPS was $10.09 and non-GAAP diluted EPS
(1)
Three FDA approvals received: Libtayo
® for first-line advanced non-small cell lung cancer (NSCLC) and advanced basal cell carcinoma (BCC), and Evkeeza
TM
Positive data reported from Phase 3 trials with REGEN-COV used to treat and prevent COVID-19
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2021 and provided a business update.
Evelo Biosciences, Inc.: Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
-Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting-
-Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors-
-Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets-
-Multiple clinical data readouts expected over next 18 months-
-Management to host conference call at 8:30 a.m. ET-
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2021.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
Evelo Biosciences, Inc.April 29, 2021 GMT
–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting– –Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors– –Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets– –Multiple clinical data readouts expected over next 18 months– –Management to host conference call at 8:30 a.m. ET–
Merck Announces First-Quarter 2021 Financial Results
First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40 … First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40